000 04306nam a22003975i 4500
001 84950
003 ES-MaUEC
005 20230207040448.0
007 cr nn 008mamaa
008 151229s2016 gw | s |||| 0|eng d
020 _a9783319236391
040 _aES-MaUEC
050 4 _aRC931.O73
_b2016 EB
082 0 4 _a616.4
245 1 4 _aThe Duration and Safety of Osteoporosis Treatment :
_bAnabolic and Antiresorptive Therapy
_cedited by Stuart Silverman, Bo Abrahamsen
250 _a1st ed.
260 _aCham
_bSpringer International Publishing
_c2016
300 _a1 recurso en línea (XVI, 338 páginas)
_b100 ilustraciones, 38 ilustraciones en color
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aForeword -- Preface -- Osteoporosis: Pathophysiology & Epidemiology -- Antiresorptives -- Anabolics -- Tools for Assessing Fracture Risk and for Treatment Monitoring -- Treatment Failure -- Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures -- Bisphosphonate-Related Atypical Femoral Fractures and Their Radiographic Features -- Factors Contributing to Atypical Femoral Fractures -- Clinical Presentation of Atypical Femur Fractures -- Effects of Antiresorptive Therapy on Bone Microarchitecture -- Management of Atypical Femoral Fractures -- Osteonecrosis of the Jaw: Clinico-Pathologic and Radiologic Features -- Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment -- Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment -- Long-Term Efficacy and Safety of Treatments for Osteoporosis -- Management of Drug Holidays -- Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant? -- Fractures and Healing on Antiresorptive Therapy -- Antiresorptive Therapy and Mortality and Cancer Incidence -- Other Safety Concerns -- The Impact of Regulatory and Scientific Organizations Recommendations on Clinical Decision Making -- Integrated Clinical View on Long-Term Management of Patients with Osteoporosis -- Conclusions.
520 3 _aProviding a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.
710 2 _aSpringerLink (Online service)
_0Local
_9106996
942 _2lcc
_cLE
650 7 _aMedicina
_0comprobar BNE19900959047
_2embne
_9405021
650 7 _aEndocrinología
_0comprobar BNE19900971669
_2embne
_9139372
700 1 _aSilverman, Stuart.
_eeditor literario
_997542
_0Local
700 1 _aAbrahamsen, Bo
_eeditor literario
_0Local
_997543
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-23639-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901 _ai9783319236391
907 _a.b12942285
_b10-10-17
_c21-11-16
988 _aSpringer_Medicine_2016
998 _am
_a_alco
_a_vill
_b - -
_cm
_dz
_e-
_feng
_ggw
_h4
945 _aRC931.O73 T443 2016 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i11586618
_z06-04-17
999 _c84950
_d84950
_x1